Conclusions
Immunotherapy outcomes in small studies have shown good data for
increasing survival rates at all yearly intervals in MM of the head and
neck. Larger clinical trials should be done to accurately distinguish
efficacy and survival outcomes of immunotherapy when compared to
treatment modalities excluding immunotherapy. The ability to perform
larger trials are, however, limited by the rarity of MM of the head and
neck.